Could a diabetes pill lift depression? new trial aims to find out

NCT ID NCT07239011

Recruiting now Symptom relief Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether dapagliflozin, a drug normally used for diabetes, can help reduce depression symptoms when added to standard antidepressant treatment. Sixty adults with moderate to severe depression will receive either dapagliflozin plus fluoxetine or fluoxetine alone. The goal is to see if the combination leads to greater improvement in mood and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin
What this could lead to: If it works, this could point toward a new, repurposed treatment option for depression, especially for people who don't respond well to current antidepressants.
What could go wrong: This is an early, small Phase 1/2 trial with only 60 participants, so results may not apply broadly. Dapagliflozin is not yet proven for depression and may cause side effects like dehydration or urinary infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION

Contacts and locations

Locations

Mostafa Bahaa
RECRUITING

Damietta, New Damietta, 34518, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.